|

Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection Clinical Trials

1 actively recruiting trial across 1 location

Also known as: PHESGO, Pertuzumab-Trastuzumab FDC SC

Pipeline

Phase 2: 1

Top Sponsors

  • MedSIR1

Indications

  • HER2-positive Breast Cancer1
  • Breast Cancer1
  • Cancer1

Boston, Massachusetts1 trial

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.